IMMUPHARMA PLC (IMM) — Corporate Update

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the IMMUPHARMA PLC Corporate Update. Throughout today's recorded meeting, attendees will be in listen only mode. Questions are encouraged. They can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Please simply type in your questions at any time and press send. Due to the significant attendance on today's call, the company may not be in a position to answer every question received during the meeting itself. However, the company can review these questions and we'll publish any responses via the platform in due course. Before we begin, we'd like to submit the following poll, and I'm sure the company would be most grateful for your participation. And I'd like to hand over to the magic team from IMMUPHARMA, Tim. Good afternoon. Thank you, Mark. Good morning, everybody. Thank you very much for joining us here today. And the purpose of today is to give a pretty detailed rundown of the details of the funding and the reasons for the funding that we announced earlier this week. And as you'll see on the screen, I've got my two colleagues with me. So let me introduce myself, chief executive officer, Tim McCarthy. On my left, your right, is doctor Sebastian Guduru, who our Chief Scientific Officer. And on my right, your left, Doctor. Tim Franklin, who is our Chief Operating Officer. And we'll all be taking different parts of the presentation to explain the details of each section. So if I can just go back to this slide here. Before we get into the detailed presentation itself, we've already had quite a number of pre submitted q and a's and various feedbacks during the week from the shareholder base. So I just wanted to address two or three pretty important key points before we ge...